Abemaciclib plus fulvestrant in treating hormone-receptor positive, HER2-negative advanced breast cancer-comparing real-world outcomes in England to the MONARCH-2 trial - PubMed
7 hours ago
- #Real-world evidence
- #Advanced breast cancer
- #Comparative effectiveness
- Abemaciclib plus fulvestrant shows shorter real-world outcomes in England compared to the MONARCH-2 trial for HR+/HER2- advanced breast cancer.
- Median overall survival (OS) was 25.9 months vs. 46.7 months in the trial, with differences unexplained by patient characteristics.
- Treatment-free survival (TFS) was 11.6 months vs. 16.9 months progression-free survival (PFS), and chemotherapy-free survival (CFS) was 15.3 months vs. 25.5 months.
- The study indicates MONARCH-2 trial data may not be generalizable to real-world clinical practice in England.